Change of Composition of the Telix Board of Directors
Telix announces that Tiffany Olson has been appointed to the Board, as a U.S.-based independent Non-Executive Director.
New Video Series “PSMA PET/CT TODAY” Discusses the Future of Prostate Cancer Care with Leading Experts
Telix is pleased to announce the launch of PSMA PET/CT Today, a five-part video series, featuring leading theranostics experts, on the role of advanced diagnostic imaging in prostate cancer care.
Telix Granted FDA Orphan Drug Designation for Bone Marrow Conditioning Treatment
Telix announces that the FDA has granted Orphan Drug Designation for TLX66 (90Y-besilesomab), for conditioning treatment prior to hematopoietic stem cell transplant (HSCT).
Telix and Xiel Sign U.K. and Ireland Distribution Agreement for Illuccix®
Telix announces agreement with Xiel for the distribution of Telix’s prostate cancer investigational imaging product, Illuccix® in the UK and Republic of Ireland
Telix Advances Development of Glioblastoma Therapy Program
Telix announces significant progress in advancing the Company’s glioblastoma therapy candidate TLX101 into the next stage of clinical development.
Telix Radiopharmaceutical Production Facility Buildout Commences
Telix provides a material update on the development of its radiopharmaceutical production facility in Brussels South (Seneffe) in the Wallonia region of Belgium.
EAU Updates Guidance for PSMA-PET Imaging
Telix welcomes the updated 2022 ‘Guidelines on Prostate Cancer’ (the Guidelines) from the European Association of Urology (EAU), which demonstrate an increasing recognition of the clinical utility of prostate specific membrane antigen (PSMA) positron emission tomography (PET) imaging modalities (PSMA PET), including gallium-68 PSMA-11, in the diagnosis of prostate cancer.
ZIRCON Phase III Kidney Cancer Imaging Study Completes Target Enrolment
Telix announces the ZIRCON Phase III study of investigational kidney cancer imaging agent, TLX250-CDx has dosed the target enrolment of 252 patients.
Telix Releases Results for the Year Ended 31 December 2021 and 2021 Annual Report
Telix Pharmaceuticals Limited Releases Full-Year 2021 Results and 2021 Annual Report.
Telix Enters Commercial Distribution Agreement for Illuccix® in Australia
Telix announces a commercial distribution agreement with Global Medical Solutions Australia (GMSA), for Illuccix® in the Australian market